Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00585845
Recruitment Status : Terminated
First Posted : January 3, 2008
Last Update Posted : February 20, 2009
Information provided by:
Anza Therapeutics, Inc.

Brief Summary:

This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment. CRS-207 has been altered in the lab to reduce its ability to cause disease, while maintaining stimulation of the immune system. CRS 207 has also been genetically modified with recombinant DNA to release an antigen called Mesothelin. Because CRS 207 stimulates an immune response to Mesothelin and Mesothelin may be present at higher levels on tumor cells than on normal cells, this clinical trial will also examine if CRS 207 boosts the immune system in a way that targets certain types of cancer.

The purpose of this first clinical trial with CRS-207 is to identify an appropriate dose of the investigation agent for later clinical studies and to explore safety when given to consenting adults with advanced cancer of the ovary or pancreas, non-small cell lung cancer, or advanced malignant epithelial mesothelioma. Immunological response to CRS-207 and tumor status of study participants will also be measured. Patients who choose to enter the study must meet all study entry criteria and must have previously failed standard treatment for their cancer. Qualifying study patients will be assigned to receive one of several dose levels of CRS-207. Each patient may receive up to 4 intravenous administrations (21 days apart) of CRS-207 at their assigned dose level.

Condition or disease Intervention/treatment Phase
Malignant Epithelial Mesothelioma Adenocarcinoma of the Pancreas Carcinoma, Non-Small-Cell Lung Adenocarcinoma of the Ovaries Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin Phase 1

Detailed Description:
Patients who consent to participate in the study will be evaluated for eligibility according to their medical history, physical examination, blood testing, and computed tomography (CT) scan of thorax, abdomen, and pelvis. Those patients who qualify for the study will receive up to 4 intravenous doses of CRS-207, 21 days apart. After each infusion, they will be monitored overnight in an in-patient facility, including collection of blood specimens. Study participants will return after each infusion for outpatient follow-up visits for further blood tests and additional monitoring of safety and immune response to CRS-207. Participants will have repeat CT scans to measure tumor size after the 2nd dose and again after the 4th dose. On Day 91 participants will be discharged from the study. All study participants will be eligible to participate in a long-term follow-up study with a visit 6 months after the final dose of CRS-207 and annually thereafter for evaluation of disease progression, survival, and potential long-term toxicity of CRS 207.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Study Start Date : December 2007
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Arm Intervention/treatment
Experimental: CRS-207 Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10^8 cfu to 1x10^10 cfu.

Primary Outcome Measures :
  1. Dose-limiting toxicities related to the investigational agent [ Time Frame: 28 days after first dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Documented malignant epithelial mesothelioma, cancer of the pancreas or ovaries or non-small-cell lung cancer (NSCLC) and who have failed (or are not candidates for) standard therapy
  2. ECOG Performance Status of 0 to 1, or Karnofsky Performance Status (KPS) of 80-100%
  3. Adequate organ function as defined by study-specified laboratory tests
  4. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug
  5. Signed informed consent form
  6. Willing and able to comply with study procedures

Exclusion Criteria:

  1. History of infection with Listeria, prior vaccination with a listeria-based vaccine, or a positive fecal culture of Listeria at screening
  2. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions
  3. Allergy to penicillin or yeast or other component of the study drug product (e.g., glycerol)
  4. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0
  5. Artificial (prosthetic) joint or other artificial implant or devices that cannot be easily removed
  6. Certain types of blood transfusions within 14 days prior to receiving study drug or a condition requiring regular blood transfusions more than twice per month
  7. Taking the following medications:

    • Anti-coagulation medications
    • Systemically active steroids for more than 2 days within 28 days prior to receiving study drug
    • More than 325 mg per day of aspirin
    • More than 2 g per day of acetaminophen
    • Systemic antibiotics within 14 days prior to receiving study drug
    • Another investigational product within 28 days prior to receiving study drug
  8. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
  9. Infection with HIV, hepatitis B or C, or HTLV-1 (human t-lymphotropic virus type 1) at screening
  10. Pregnant or lactating, or close contact with pregnant women or newborn babies
  11. Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00585845

Layout table for location information
United States, Maryland
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland, United States, 21231
National Cancer Institute, NCI
Bethesda, Maryland, United States, 20892
United States, Pennsylvania
University of Pennsylvania Abramson Family Cancer Research Center
Philadelphia, Pennsylvania, United States, 19104
Hadassah Hebrew University Medical Center
Jerusalem, Israel, 91120
Sponsors and Collaborators
Anza Therapeutics, Inc.
Layout table for investigator information
Study Director: Dung Thai Anza Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Dung Thai, Anza Therapeutics, Inc. Identifier: NCT00585845    
Other Study ID Numbers: VAC07001
First Posted: January 3, 2008    Key Record Dates
Last Update Posted: February 20, 2009
Last Verified: February 2009
Keywords provided by Anza Therapeutics, Inc.:
Ovarian cancer
Pancreatic cancer
Non-small cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma, Malignant
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Pleural Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms